Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.
暂无分享,去创建一个
[1] S. Parija,et al. Candida parapsilosis: an emerging fungal pathogen , 2012, The Indian journal of medical research.
[2] K. Rappersberger,et al. Primary cutaneous infection with Scedosporium apiospermum successfully treated with voriconazole , 2011, Mycoses.
[3] E. Ito,et al. Voriconazole for both successful treatment of disseminated Trichosporon asahii infection and subsequent cord blood transplantation in an infant with acute myelogenous leukemia , 2011, Bone Marrow Transplantation.
[4] J. Guarro,et al. Apophysomyces variabilis Infections in Humans , 2011, Emerging infectious diseases.
[5] J. Guarro,et al. Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine. , 2011, International journal of antimicrobial agents.
[6] J. Guarro,et al. Combined Therapy Against Murine-Disseminated Infection by Fusarium verticillioides , 2011, Mycopathologia.
[7] F. Barchiesi,et al. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. , 2010, The Journal of antimicrobial chemotherapy.
[8] J. Guarro,et al. In Vitro and In Vivo Antifungal Susceptibilities of the Mucoralean Fungus Cunninghamella , 2010, Antimicrobial Agents and Chemotherapy.
[9] D. Lung,et al. Intra-abdominal Rhizopus microsporus Infection Successfully Treated by Combined Aggressive Surgical, Antifungal, and Iron Chelating Therapy , 2010, Journal of pediatric hematology/oncology.
[10] F. Grenouillet,et al. International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole , 2010, Antimicrobial Agents and Chemotherapy.
[11] M. Briones,et al. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] J. Guarro,et al. Antifungal therapies in murine disseminated phaeohyphomycoses caused by Exophiala species. , 2010, The Journal of antimicrobial chemotherapy.
[13] J. Guarro,et al. Experimental Murine Scedosporiosis: Histopathology and Azole Treatment , 2010, Antimicrobial Agents and Chemotherapy.
[14] J. Guarro,et al. Correlation between InVitro Activity of Posaconazole and InVivo Efficacy against Rhizopus oryzae Infection in Mice , 2010, Antimicrobial Agents and Chemotherapy.
[15] J. Guarro,et al. Efficacy of voriconazole in a murine model of invasive paecilomycosis. , 2010, International journal of antimicrobial agents.
[16] J. Guarro,et al. Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. , 2010, Revista iberoamericana de micologia.
[17] P. Le Pape,et al. Disseminated Scedosporium/Pseudallescheria Infection after Double-Lung Transplantation in Patients with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.
[18] F. Gumy-Pause,et al. Report of a Successful Treatment of Pulmonary Cunninghamella bertholletiae Infection With Liposomal Amphotericin and Posaconazole in a Child With GvHD and Review of the Literature , 2010, Journal of pediatric hematology/oncology.
[19] J. Guarro,et al. Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection. , 2010, International journal of antimicrobial agents.
[20] J. Graybill,et al. Efficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani , 2010, Antimicrobial Agents and Chemotherapy.
[21] P. Koistinen,et al. Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs. , 2010, Medical mycology.
[22] J. Guarro,et al. Murine Model of a Disseminated Infection by the Novel Fungus Fonsecaea monophora and Successful Treatment with Posaconazole , 2009, Antimicrobial Agents and Chemotherapy.
[23] D. Stevens,et al. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility , 2009, Critical reviews in microbiology.
[24] J. Guarro,et al. Efficacy of Posaconazole in a Murine Disseminated Infection by Candida tropicalis , 2009, Antimicrobial Agents and Chemotherapy.
[25] J. Guarro,et al. Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. , 2009, International journal of antimicrobial agents.
[26] J. Guarro,et al. Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy , 2009, Antimicrobial Agents and Chemotherapy.
[27] J. Guarro,et al. Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection , 2009, Antimicrobial Agents and Chemotherapy.
[28] James Evans,et al. Case of Fatal Blastoschizomyces capitatus Infection Occurring in a Patient Receiving Empiric Micafungin Therapy , 2009, Antimicrobial Agents and Chemotherapy.
[29] J. Guarro,et al. Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. , 2009, Medical mycology.
[30] Y. Aoyama,et al. Subcutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a non-Hodgkin lymphoma patient. , 2009, Medical mycology.
[31] S. de Hoog,et al. Eumycetoma caused by Cladophialophora bantiana successfully treated with itraconazole. , 2009, Medical mycology.
[32] T. Sorrell,et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[33] D. Marriott,et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[34] B. Spellberg,et al. Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] J. Guarro,et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. , 2009, Medical mycology.
[36] J. Guarro,et al. Different virulence of the species of the Pseudallescheria boydii complex. , 2009, Medical mycology.
[37] J. Guarro,et al. High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. , 2009, The Journal of antimicrobial chemotherapy.
[38] G. S. Hoog,et al. Cerebral phaeohyphomycosis--a cure at what lengths? , 2009, The Lancet. Infectious diseases.
[39] J. Guarro,et al. Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei , 2009, Antimicrobial Agents and Chemotherapy.
[40] J. Guarro,et al. Efficacy of Liposomal Amphotericin B Combined with Gamma Interferon or Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Systemic Zygomycosis in Mice , 2009, Antimicrobial Agents and Chemotherapy.
[41] M. De Curtis,et al. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. , 2009, The Pediatric infectious disease journal.
[42] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] J. Guarro,et al. Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans , 2009, Antimicrobial Agents and Chemotherapy.
[44] J. Guarro,et al. Interactions between Triazoles and Amphotericin B in Treatment of Disseminated Murine Infection by Fusarium oxysporum , 2009, Antimicrobial Agents and Chemotherapy.
[45] Suhail Ahmad,et al. Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole , 2009, Journal of Clinical Microbiology.
[46] V. Paetznick,et al. Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-d-Glucan Levels , 2009, Antimicrobial Agents and Chemotherapy.
[47] J. Guarro,et al. Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. , 2008, The Journal of antimicrobial chemotherapy.
[48] D. Denning,et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. , 2008, The Journal of antimicrobial chemotherapy.
[49] A. Pasqualotto. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. , 2009, Medical mycology.
[50] M. Cuenca‐Estrella,et al. Disseminated Fusariosis Caused by Fusarium verticillioides in an Acute Lymphoblastic Leukemia Patient after Allogeneic Hematopoietic Stem Cell Transplantation , 2008, Journal of Clinical Microbiology.
[51] M. E. Tosello,et al. Systemic infection caused by Trichosporon asahii in a patient with liver transplant. , 2008, Medical mycology.
[52] J. Graybill,et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. , 2008, The Journal of antimicrobial chemotherapy.
[53] B. Spellberg,et al. Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.
[54] A. Tortorano,et al. Invasive Aspergillus nidulans infection in a patient with chronic granulomatous disease , 2008, Mycoses.
[55] J. Guarro,et al. Combined therapy in treatment of murine infection by Fusarium solani. , 2008, The Journal of antimicrobial chemotherapy.
[56] A. Pasqualotto,et al. Invasive pulmonary aspergillosis due to a mixed infection caused by Aspergillus flavus and Aspergillus fumigatus. , 2008, Revista iberoamericana de micologia.
[57] J. Guarro,et al. Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae , 2008, Antimicrobial Agents and Chemotherapy.
[58] C. Lutz,et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.
[59] P. Bijlenga,et al. Cladophialophora bantiana: a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options. , 2008, Medical mycology.
[60] G. S. de Hoog,et al. Aspergillus flavus myositis in a patient after liver transplantation , 2008, Clinical transplantation.
[61] Kerry O'Donnell,et al. Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex , 2008, Journal of Clinical Microbiology.
[62] C. Gianni,et al. Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy , 2008, Antimicrobial Agents and Chemotherapy.
[63] F. Barchiesi,et al. Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole , 2008, Antimicrobial Agents and Chemotherapy.
[64] J. Guarro,et al. In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum , 2008, Antimicrobial Agents and Chemotherapy.
[65] J. Garbino,et al. New azoles as first line therapy for Paecilomyces lilacinus in transplant patients , 2008, Transplant infectious disease : an official journal of the Transplantation Society.
[66] J. Guarro,et al. Micafungin combined with fluconazole, an effective therapy for murine blastoschizomycosis. , 2008, The Journal of antimicrobial chemotherapy.
[67] J. Guarro,et al. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata. , 2008, The Journal of antimicrobial chemotherapy.
[68] E. Mellado,et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. , 2008, The Journal of antimicrobial chemotherapy.
[69] M. Gobbi,et al. A Case of Cunninghamella bertholettiae Rhino-cerebral Infection in a Leukaemic Patient and Review of Recent Published Studies , 2008, Mycopathologia.
[70] J. Fournet,et al. Fatal disseminated Trichosporon asahii infection in a child with acute lymphoblastic leukemia. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[71] M. Battegay,et al. Candida krusei– a serious complication in patients with hematological malignancies: successful treatment with caspofungin , 2008, Transplant infectious disease : an official journal of the Transplantation Society.
[72] D. Stevens,et al. Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.
[73] D. Ellis,et al. Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients , 2008, Antimicrobial Agents and Chemotherapy.
[74] B. Spellberg,et al. Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.
[75] A. Safdar,et al. Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection , 2008, Leukemia & lymphoma.
[76] D. Sofianou,et al. PULMONARY ZYGOMYCOSIS CAUSED BY CUNNINGHAMELLA BERTHOLLETIAE IN A CHILD , 2002, Hippokratia.
[77] J. Guarro,et al. Molecular and Phenotypic Data Supporting Distinct Species Statuses for Scedosporium apiospermum and Pseudallescheria boydii and the Proposed New Species Scedosporium dehoogii , 2007, Journal of Clinical Microbiology.
[78] R. Barton,et al. Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 , 2007, Journal of Clinical Microbiology.
[79] F. Barchiesi,et al. Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B , 2007, Antimicrobial Agents and Chemotherapy.
[80] D. Hospenthal,et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. , 2007, Medical mycology.
[81] D. Stevens,et al. Animal models: an important tool in mycology , 2007, Medical mycology.
[82] M. Baccarani,et al. Update on the treatment of disseminated fusariosis: Focus on voriconazole , 2007, Therapeutics and clinical risk management.
[83] M. Reijnen,et al. Successful treatment of Scedosporium aurantiacum osteomyelitis in an immunocompetent patient. , 2007, Surgical infections.
[84] B. Ferhanoğlu,et al. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] Sang Il Kim,et al. Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient. , 2007, Annals of clinical and laboratory science.
[86] G. S. de Hoog,et al. Spectrum of Clinically Relevant Exophiala Species in the United States , 2007, Journal of Clinical Microbiology.
[87] P. Stiff,et al. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections , 2007 .
[88] D. Denning,et al. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. , 2007, Microbiology.
[89] J. Guarro,et al. Combined Therapies in a Murine Model of Blastoschizomycosis , 2007, Antimicrobial Agents and Chemotherapy.
[90] J. Toquero,et al. Aspergillus infection of implantable cardioverter-defibrillators and pacemakers: case report and literature review , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[91] K. Marr,et al. Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase , 2007, Antimicrobial Agents and Chemotherapy.
[92] J. Graybill,et al. In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera , 2007, Antimicrobial Agents and Chemotherapy.
[93] J. Guarro,et al. Universal In Vitro Antifungal Resistance of Genetic Clades of the Fusarium solani Species Complex , 2007, Antimicrobial Agents and Chemotherapy.
[94] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[95] N. Okhravi,et al. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[96] J. Guarro,et al. Effect of antifungal treatment in a murine model of blastoschizomycosis. , 2007, International journal of antimicrobial agents.
[97] S. Rishi,et al. Neuroaspergillosis in an immunocompetent patient. , 2007, Indian journal of medical microbiology.
[98] G. Drusano,et al. Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia , 2006, Antimicrobial Agents and Chemotherapy.
[99] F. Barchiesi,et al. Caspofungin in Combination with Amphotericin B against Candida parapsilosis , 2006, Antimicrobial Agents and Chemotherapy.
[100] J. Guarro,et al. Combined antifungal therapy in a murine infection by Candida glabrata. , 2006, The Journal of antimicrobial chemotherapy.
[101] D. Denning,et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. , 2006, The Journal of antimicrobial chemotherapy.
[102] B. Spellberg,et al. Comparison of antifungal treatments for murine fusariosis. , 2006, The Journal of antimicrobial chemotherapy.
[103] G. Shankland,et al. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. , 2006, Medical mycology.
[104] A. Santinelli,et al. Posaconazole Prophylaxis in Experimental Systemic Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.
[105] P. Liberator,et al. Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans , 2006, Antimicrobial Agents and Chemotherapy.
[106] J. Guarro,et al. Antifungal Susceptibilities of the Species of the Pseudallescheria boydii Complex , 2006, Antimicrobial Agents and Chemotherapy.
[107] F. Baldelli,et al. Clinical Efficacy and Tolerability of Caspofungin in a Renal Transplant Patient with Aspergillus flavus Lung Infection: Case Report , 2006, Journal of chemotherapy.
[108] C. Kibbler,et al. Candida rugosa, an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program , 2006, Journal of Clinical Microbiology.
[109] C. Kibbler,et al. Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program , 2006, Journal of Clinical Microbiology.
[110] J. Rosenecker,et al. Posaconazole for treatment of refractory invasive fungal disease , 2006, Mycoses.
[111] George L. Drusano,et al. Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.
[112] D. Stevens,et al. Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them? , 2006, Medical mycology.
[113] D. Stevens,et al. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions , 2006, Current opinion in infectious diseases.
[114] F. Barchiesi,et al. Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis , 2006, Antimicrobial Agents and Chemotherapy.
[115] B. Ener,et al. Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia , 2006, Annals of Clinical Microbiology and Antimicrobials.
[116] J. Staab,et al. Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy , 2006, Antimicrobial Agents and Chemotherapy.
[117] D. Loebenberg,et al. Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection , 2006, Antimicrobial Agents and Chemotherapy.
[118] D. Craven,et al. Fusarium oxysporum Pneumonia in an Immunocompetent Host , 2006, Southern medical journal.
[119] J. Guarro,et al. Efficacy of Voriconazole in a Guinea Pig Model of Invasive Trichosporonosis , 2006, Antimicrobial Agents and Chemotherapy.
[120] Russell E. Lewis,et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. , 2006, The Journal of infectious diseases.
[121] A. Lazzarin,et al. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. , 2006, The Journal of antimicrobial chemotherapy.
[122] D. Kontoyiannis,et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[123] S. Filler,et al. Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[124] M. Schuster,et al. Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.
[125] J. Fraser,et al. Aspergillus flavus endocarditis--to prevaricate is to posture. , 2006, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.
[126] J. Adler-Moore,et al. Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin , 2005, Antimicrobial Agents and Chemotherapy.
[127] Steve A. Hernandez,et al. Caspofungin and Liposomal Amphotericin B Therapy of Experimental Murine Scedosporiosis , 2005, Antimicrobial Agents and Chemotherapy.
[128] A. Santinelli,et al. Efficacy of Caspofungin against Aspergillus terreus , 2005, Antimicrobial Agents and Chemotherapy.
[129] George L. Drusano,et al. Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity , 2005, Antimicrobial Agents and Chemotherapy.
[130] J. Guarro,et al. Activities of Flucytosine, Fluconazole, Amphotericin B, and Micafungin in a Murine Model of Disseminated Infection by Candida glabrata , 2005, Antimicrobial Agents and Chemotherapy.
[131] J. Guarro,et al. Molecular Phylogeny of the Pseudallescheria boydii Species Complex: Proposal of Two New Species , 2005, Journal of Clinical Microbiology.
[132] M. Lyons,et al. Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana , 2005, Clinical Neurology and Neurosurgery.
[133] G. Forrest,et al. Prevalence of Candida dubliniensis fungemia at a large teaching hospital. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[134] M. Dierich,et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10‐year single centre experience , 2005, British journal of haematology.
[135] P. Pitisuttithum,et al. Activity of posaconazole in the treatment of central nervous system fungal infections. , 2005, The Journal of antimicrobial chemotherapy.
[136] T. Walsh,et al. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. , 2005, Medical mycology.
[137] D. Denning,et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. , 2005, The Journal of antimicrobial chemotherapy.
[138] M. Rinaldi,et al. Caspofungin in Combination with Amphotericin B against Candida glabrata , 2005, Antimicrobial Agents and Chemotherapy.
[139] J. Graybill,et al. Antifungal Therapy of Experimental Cerebral Phaeohyphomycosis Due to Cladophialophora bantiana , 2005, Antimicrobial Agents and Chemotherapy.
[140] R. Summerbell,et al. Fusarium verticillioides Abscess of the Nasal Septum in an Immunosuppressed Child: Case Report and Identification of the Morphologically Atypical Fungal Strain , 2005, Journal of Clinical Microbiology.
[141] B. Spellberg,et al. Caspofungin Inhibits Rhizopus oryzae 1,3-β-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis , 2005, Antimicrobial Agents and Chemotherapy.
[142] J. Al-Tawfiq,et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. , 2005, Medical mycology.
[143] J. Guarro,et al. Efficacy of Micafungin in Combination with Other Drugs in a Murine Model of Disseminated Trichosporonosis , 2005, Antimicrobial Agents and Chemotherapy.
[144] B. Spellberg,et al. Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.
[145] Maria José Figueras,et al. Atlas of clinical fungi. , 2005 .
[146] D. Stevens,et al. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. , 2005, Medical mycology.
[147] J. Guarro,et al. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. , 2004, Diagnostic microbiology and infectious disease.
[148] J. Guarro,et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. , 2004, The Journal of antimicrobial chemotherapy.
[149] J. Robinson,et al. Genetic Diversity of Human Pathogenic Members of the Fusarium oxysporum Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin , 2004, Journal of Clinical Microbiology.
[150] F. Barchiesi,et al. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. , 2004, Diagnostic microbiology and infectious disease.
[151] J. Guarro,et al. Correlation between In Vitro Susceptibility of Scedosporium apiospermum to Voriconazole and In Vivo Outcome of Scedosporiosis in Guinea Pigs , 2004, Antimicrobial Agents and Chemotherapy.
[152] G. D. Hoog,et al. Molecular ecology and pathogenic potential of Fonsecaea species. , 2004, Medical mycology.
[153] Ray Y. Hachem,et al. Aspergillus terreus , 2004, Cancer.
[154] Steve A. Hernandez,et al. Antifungal Therapy of Murine Aspergillus terreus Infection , 2004, Antimicrobial Agents and Chemotherapy.
[155] J. Perfect,et al. In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection , 2004, Antimicrobial Agents and Chemotherapy.
[156] B. Suh,et al. Cladophialophora bantiana Brain Abscess in a Solid-Organ Transplant Recipient: Case Report and Review of the Literature , 2004, Journal of Clinical Microbiology.
[157] T. Walsh,et al. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. , 2004, The Pediatric infectious disease journal.
[158] M. Bassetti,et al. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. , 2004, The Journal of antimicrobial chemotherapy.
[159] Steve A. Hernandez,et al. Alternatives to amphotericin B for Candida rugosa infection. , 2004, The Journal of antimicrobial chemotherapy.
[160] D. Loebenberg,et al. Posaconazole Therapy of Disseminated Phaeohyphomycosis in a Murine Model , 2004, Antimicrobial Agents and Chemotherapy.
[161] Lee H. Harrison,et al. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.
[162] Steve A. Hernandez,et al. Activity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories , 2004, Antimicrobial Agents and Chemotherapy.
[163] R. Negroni,et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[164] J. Sierra,et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[165] G. S. Hoog,et al. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004 , 2004, Mycoses.
[166] M. Rinaldi,et al. Primary central nervous system phaeohyphomycosis: a review of 101 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[167] A. Honda. A murine model of zygomycosis by Cunninghamella bertholletiae , 1998, Mycopathologia.
[168] K. Gyure. Infections of the Central Nervous System , 2004 .
[169] M. C. Dignani,et al. Human fusariosis. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[170] L. Contu,et al. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.
[171] H. Seifert,et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B , 2004, Annals of Hematology.
[172] J. Guarro,et al. Efficacy of Voriconazole in Treatment of Systemic Scedosporiosis in Neutropenic Mice , 2003, Antimicrobial Agents and Chemotherapy.
[173] T. Rogers,et al. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[174] J. Meis,et al. Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis , 2003, Antimicrobial Agents and Chemotherapy.
[175] G. S. de Hoog,et al. Exophiala oligosperma Causing Olecranon Bursitis , 2003, Journal of Clinical Microbiology.
[176] B. Spellberg,et al. Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae , 2003, Antimicrobial Agents and Chemotherapy.
[177] R. Salomão,et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. , 2003, Diagnostic microbiology and infectious disease.
[178] M. Ghannoum,et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. , 2003, The Journal of infectious diseases.
[179] J. Guarro,et al. Efficacy of Albaconazole (UR-9825) in Treatment of Disseminated Scedosporium prolificans Infection in Rabbits , 2003, Antimicrobial Agents and Chemotherapy.
[180] Steve A. Hernandez,et al. Improving the mouse model for studying the efficacy of voriconazole. , 2003, The Journal of antimicrobial chemotherapy.
[181] Cheng-yi Liu,et al. Aspergillus flavus epidural abscess and osteomyelitis in a diabetic patient. , 2003, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[182] D. Loebenberg,et al. Activity of Posaconazole against Pseudallescheria boydii: In Vitro and In Vivo Assays , 2003, Antimicrobial Agents and Chemotherapy.
[183] D. Denning,et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. , 2003, Journal of Antimicrobial Chemotherapy.
[184] V. Sakhuja,et al. Apophysomyces elegans: an Emerging Zygomycete in India , 2003, Journal of Clinical Microbiology.
[185] H. Khoury,et al. Acute Myelogenous Leukemia Complicated by Acute Necrotizing Ulcerative Gingivitis Due to Aspergillus terreus , 2003, Leukemia & lymphoma.
[186] D. Denning,et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. , 2002, The Journal of antimicrobial chemotherapy.
[187] B. Gordts,et al. Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[188] D. Loebenberg,et al. In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model , 2002, Antimicrobial Agents and Chemotherapy.
[189] J. Guarro,et al. Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis , 2002, Antimicrobial Agents and Chemotherapy.
[190] J. Meis,et al. Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis , 2002, Antimicrobial Agents and Chemotherapy.
[191] S. Holland,et al. Efficacies of Fluconazole, Caspofungin, and Amphotericin B in Candida glabrata-Infected p47phox−/− Knockout Mice , 2002, Antimicrobial Agents and Chemotherapy.
[192] J. Guarro,et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. , 2002, The Journal of antimicrobial chemotherapy.
[193] D. Niederwieser,et al. Secondary cutaneous aspergillosis due to Aspergillus flavus in an acute myeloid leukaemia patient following stem cell transplantation. , 2002, European journal of dermatology : EJD.
[194] E. Roilides,et al. Case Report. Hepatic abscesses due to Aspergillus terreus in an immunodeficient child , 2001, Mycoses.
[195] P. Warn,et al. Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. , 2001, The Journal of antimicrobial chemotherapy.
[196] G. Pankey,et al. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[197] D. Denning,et al. Susceptibility Testing of Aspergillus flavus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo , 2001, Antimicrobial Agents and Chemotherapy.
[198] J. Graybill. The role of murine models in the development of antifungal therapy for systemic mycoses. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[199] T. Hall,et al. Mycotic aneurysm of the thoracic aorta due to Aspergillus terreus: case report and review. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[200] D. Loebenberg,et al. In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida , 2000, Antimicrobial Agents and Chemotherapy.
[201] E. Borel,et al. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. , 2000, Journal of medical microbiology.
[202] D. Loebenberg,et al. SCH 56592, Amphotericin B, or Itraconazole Therapy of Experimental Murine Cerebral Phaeohyphomycosis Due toRamichloridium obovoideum (“Ramichloridium mackenziei”) , 2000, Antimicrobial Agents and Chemotherapy.
[203] D. Loebenberg,et al. Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys , 2000, Antimicrobial Agents and Chemotherapy.
[204] V. Saha,et al. MEDICAL MANAGEMENT OF ASPERGILLUS FLAVUS ENDOCARDITIS , 2000, Pediatric hematology and oncology.
[205] D. Denning,et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. , 2000, The Journal of antimicrobial chemotherapy.
[206] A. Sugar,et al. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. , 2000, Medical mycology.
[207] J. Guarro,et al. In Vitro and In Vivo Experimental Activities of Antifungal Agents against Fusarium solani , 1999, Antimicrobial Agents and Chemotherapy.
[208] E. Anaissie,et al. Treatment of Murine Fusariosis with SCH 56592 , 1999, Antimicrobial Agents and Chemotherapy.
[209] J. Guarro,et al. Antifungal Susceptibilities ofPaecilomyces Species , 1998, Antimicrobial Agents and Chemotherapy.
[210] M. Ghannoum,et al. Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models , 1998, Antimicrobial Agents and Chemotherapy.
[211] A. Polak. Experimental models in antifungal chemotherapy , 1998, Mycoses.
[212] J. Smith,et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis , 1997, Antimicrobial agents and chemotherapy.
[213] J. Graybill,et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 , 1997, Antimicrobial agents and chemotherapy.
[214] A. Chakrabarti,et al. Rabbit as an animal model of paranasal sinus mycoses. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[215] J. Galgiani,et al. Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal , 1997, Journal of clinical microbiology.
[216] J. Nedelman,et al. Pharmacokinetics and Pharmacodynamics of Multiple‐Dose Terbinafine , 1996, Journal of clinical pharmacology.
[217] D. D’Antonio,et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients , 1996, Journal of clinical microbiology.
[218] D. Stevens. Animal models in the evaluation of antifungal drugs , 1996 .
[219] L. Muglia,et al. Knockout mice. , 1996, The New England journal of medicine.
[220] C. Bouthet,et al. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. , 1995, The Journal of antimicrobial chemotherapy.
[221] P. Della‐Latta,et al. Mucor ramosissimus Samutsevitsch isolated from a thigh lesion , 1993, Journal of clinical microbiology.
[222] E. Anaissie,et al. Lack of activity of amphotericin B in systemic murine fusarial infection. , 1992, The Journal of infectious diseases.
[223] J. V. van Cutsem,et al. Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. , 1989, Chemotherapy.
[224] A. Polak. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. , 1987, Chemotherapy.
[225] A. Polak,et al. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. , 1987, Chemotherapy.
[226] S. Olenchock,et al. In vivo pulmonary response to Aspergillus terreus spores. , 1983, Comparative immunology, microbiology and infectious diseases.
[227] E. Block,et al. Experimental Therapy of Cladosporiosis and Sporotrichosis with 5-Fluorocytosine , 1973, Antimicrobial Agents and Chemotherapy.